bmseed
Private Company
Funding information not available
Overview
BMSEED is a private, early-stage biotech tools company founded in 2020 and based in San Francisco. It has developed the MEASSuRE platform, which features proprietary stretchable multielectrode arrays (sMEAs) to apply controlled mechanical strain while simultaneously recording and stimulating electrophysiological activity in cell and tissue cultures. This integrated approach addresses a critical limitation in conventional in vitro models by replicating in vivo biomechanics, potentially improving the predictive power of preclinical research in neuroscience, cardiology, and trauma. The company appears to be pre-revenue, focusing on research collaborations and publications to validate its platform for academic and industrial research customers.
Technology Platform
MEASSuRE platform featuring stretchable multielectrode arrays (sMEAs) that integrate controlled mechanical stretching, real-time optical imaging, and multielectrode array (MEA) electrophysiology in a single in vitro system.
Opportunities
Risk Factors
Competitive Landscape
BMSEED competes in the electrophysiology tools space against established players like Axion BioSystems and MaxWell Biosystems (offering static MEA systems), and in biomechanics with companies producing cell-stretching devices. Its key differentiator is the direct integration of these two modalities on a single, stretchable electrode substrate, a niche currently with few direct competitors.